![Nicolas Leupin](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Nicolas Leupin
Keine laufenden Positionen mehr
Vermögen: 2 Mio $ am 31.07.2026
Profil
Nicolas Leupin worked as Chief Medical Officer at argenx SE from 2016 to 2019 and at Molecular Partners AG from 2019 to 2023.
Also held the position of Chief Medical Officer at NovoCure Ltd. and was a Member of the Swiss Group for Clinical Research.
Education includes a doctorate from the University of Bern and an MBA from Jones International University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
NOVOCURE LTD. 0,09 % | 06.04.2026 | 102.979 ( 0,09 % ) | 2 Mio $ | 31.07.2026 |
Ehemalige bekannte Positionen von Nicolas Leupin
| Unternehmen | Position | Ende |
|---|---|---|
| MOLECULAR PARTNERS AG | Technik-/Wissenschafts-/F&E-Leiter | 24.08.2023 |
| ARGENX SE | Technik-/Wissenschafts-/F&E-Leiter | 01.07.2019 |
| NOVOCURE LIMITED | Technik-/Wissenschafts-/F&E-Leiter | - |
Swiss Group for Clinical Research | Corporate Officer/Principal | - |
Ausbildung von Nicolas Leupin
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
28
Beziehungen ersten Grades
6
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 6 |
|---|---|
Jones International University
 Jones International University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Bern
 University of Bern Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Molecular Partners AG
 Molecular Partners AG BiotechnologyHealth Technology Engages in discovery, development and commercialization of biopharmaceutical products | Health Technology |
NovoCure Ltd.
 NovoCure Ltd. Medical SpecialtiesHealth Technology Operates as a commercial-stage oncology company | Health Technology |
argenx SE
 argenx SE BiotechnologyHealth Technology Develops therapies and medicines for the treatment of autoimmune diseases | Health Technology |
Swiss Group for Clinical Research |
